Tarsus Pharmaceuticals, Inc.
TARS
Classifica tra le azioni
#4561
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Prezzo delle azioni
$70.82
Ultima sincronizzazione: 2026-10-21
Capitalizzazione di mercato
$3.31B
Variazione (1 giorno)
-0.30%
Variazione (1 anno)
3.08%
Paese
US
Scambia Tarsus Pharmaceuticals, Inc. (TARS)
Categoria
Healthcare
Storico del prezzo dell'azione per Tarsus Pharmaceuticals, Inc. (TARS)
Prezzo di chiusura più alto: $72.26 il 2026-10-01
Prezzo di chiusura più basso: $21.51 il 2020-10-01
Prezzo di chiusura più basso: $21.51 il 2020-10-01
Storico del prezzo dell'azione di Tarsus Pharmaceuticals, Inc. dal 2020 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $760.40 | 8.08% |
CH
|
